NetWorth
LeaderPortfolio
family
Andreas Struengmann & family
Rank #305
GERMANY•Healthcare•Pharmaceuticals

Andreas Struengmann & family

Net Worth
$10.746B
-0.17% (24h)
Andreas Strüngmann, a German physician and entrepreneur, built his fortune in the pharmaceutical and biotechnology sectors. Alongside his twin brother, Thomas, he co-founded Hexal AG, a leading generic drug manufacturer, which they sold to Novartis for $7.5 billion. Their early investment in BioNTech, a company specializing in mRNA technology, proved pivotal, especially with the development of a COVID-19 vaccine. Currently, he is managing their family assets. His career exemplifies strategic investments and a commitment to innovation in healthcare, resulting in a net worth of $14.6 billion.

How to read Andreas Struengmann & family's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Andreas Struengmann & family, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $10.746B alongside global rank #305, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (GERMANY) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Andreas Strüngmann was born in 1950 in Mülheim an der Ruhr, Germany. He earned a medical degree from the University at Buffalo. Together with his identical twin brother, Thomas, he joined their father's pharmaceutical company, Durachemie, gaining industry experience.

Rise to Success

In 1986, the Strüngmann brothers co-founded Hexal AG, a generic drug manufacturer, which grew to become Germany's second-largest. They sold Hexal and their stake in U.S. Eon Labs to Novartis in 2005 for $7.5 billion. After the sale of Hexal, they shifted their focus to biotech and healthcare investments, establishing investment firms like Santo Holding and Athos Service. In 2008, they invested in BioNTech, which later collaborated with Pfizer to produce a successful COVID-19 vaccine.

Key Business Strategies

The Strüngmanns' success stems from strategic investments in pharmaceuticals and biotechnology. They identify and support high-potential ventures. Their early investment in BioNTech and the development of the COVID-19 vaccine significantly boosted their wealth. They focus on long-term investments and innovation, especially in the healthcare sector.

Philanthropy

Andreas and his wife established the Andreas and Susan Struengmann Foundation in 2007 to support educational initiatives. They also founded the Ernst Strüngmann Institute for neuroscience research.

Career Timeline

2008

Invested in BioNTech

Made an early investment in BioNTech, a biotechnology company specializing in mRNA technology.

2005

Sold Hexal AG

Sold Hexal AG and their stake in U.S.-based Eon Labs to Novartis for $7.5 billion.

1986

Co-founded Hexal AG

Co-founded Hexal AG, a generic drug manufacturer, with his brother, Thomas.

1979

Joined Durachemie

Joined their father's pharmaceutical company, Durachemie, with his twin brother, Thomas.

Philanthropic Impact

EducationUndisclosed

Andreas and Susan Struengmann Foundation

Supports educational initiatives in the Western Cape.

ScienceUndisclosed

Ernst Strüngmann Institute

Neuroscience research center in Frankfurt

Key Business Ventures & Holdings

CompanyStakeValue
BioNTech43.50%$14M

Net Worth History

In-Depth Analysis

Early Life

Andreas Strüngmann was born in 1950 in Mülheim an der Ruhr, Germany. He earned a medical degree from the University at Buffalo. Together with his identical twin brother, Thomas, he joined their father's pharmaceutical company, Durachemie, gaining industry experience.

Rise to Success

In 1986, the Strüngmann brothers co-founded Hexal AG, a generic drug manufacturer, which grew to become Germany's second-largest. They sold Hexal and their stake in U.S. Eon Labs to Novartis in 2005 for $7.5 billion. After the sale of Hexal, they shifted their focus to biotech and healthcare investments, establishing investment firms like Santo Holding and Athos Service. In 2008, they invested in BioNTech, which later collaborated with Pfizer to produce a successful COVID-19 vaccine.

Key Business Strategies

The Strüngmanns' success stems from strategic investments in pharmaceuticals and biotechnology. They identify and support high-potential ventures. Their early investment in BioNTech and the development of the COVID-19 vaccine significantly boosted their wealth. They focus on long-term investments and innovation, especially in the healthcare sector.

Philanthropy

Andreas and his wife established the Andreas and Susan Struengmann Foundation in 2007 to support educational initiatives. They also founded the Ernst Strüngmann Institute for neuroscience research.

Data Sources & Methodology

Figures for Andreas Struengmann & family are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom